Drug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South Africa.

BACKGROUND: Emergence of HIV-1 drug resistance is at times an inevitable and anticipated consequence of antiretroviral therapy (ART) failure. We examined drug resistance patterns and virus re-suppression among subtype C-infected South African patients receiving first-line ART. METHODS: Treatment records of 431 patients on NNRTI-containing regimens for a median of 45 months were analyzed. Patients with viral load (VL) >400 copies/mL were followed and drug resistance mutations (DRM) were re-assessed. Associations between clinical/demographic measures and drug resistance/virologic outcomes were examined using Fisher exact and ordinal and logistic regression. RESULTS: Ten percent of patients (43/431) were viremic at enrollment (98% previously suppressed); sequences were obtained from 38/43. Of those, 82% had 1-7 DRM. In bivariate analysis remote exposure to single-dose nevirapine or prior ART; higher CD4 counts; lower VL; and >6 months of virologic failure were significantly associated with number of DRM. Of 25 viremic patients followed for a median of 8 months on a continued first-line regimen, 12 (48%) re-suppressed, six with K103N and three with M184V. Thirteen (52%) had continued virologic failure which was significantly associated with detectable VL>6 months prior to enrollment and number of DRM. CONCLUSION: Among these HIV-1 subtype C-infected patients, DRM numbers and patterns were associated with prior exposure to sub-optimal ART, adherence and duration of virologic failure. Viral re-suppression in the presence of K103N and M184V challenges assumptions about drug resistance. In resource-limited settings, where genotyping and alternative drug options are unavailable, continuing first-line treatment, reinforcing adherence and regular virologic monitoring may be effective even after virologic failure.

[1]  D. Mant,et al.  Associations With Virologic Treatment Failure in Adults on Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[2]  D. Katzenstein,et al.  Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa , 2010, AIDS.

[3]  Ian Sanne,et al.  Varied Patterns of HIV-1 Drug Resistance on Failing First-Line Antiretroviral Therapy in South Africa , 2010, Journal of acquired immune deficiency syndromes.

[4]  H. Fleury,et al.  Analysis of RT sequences of subtype C HIV-type 1 isolates from indian patients at failure of a first-line treatment according to clinical and/or immunological WHO guidelines. , 2010, AIDS research and human retroviruses.

[5]  A. Wensing,et al.  Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. , 2010, The Lancet. Infectious diseases.

[6]  R. Chaisson,et al.  Viremia, resuppression, and time to resistance in human immunodeficiency virus (HIV) subtype C during first-line antiretroviral therapy in South Africa. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  D. Richman,et al.  Update of the drug resistance mutations in HIV-1: December 2009. , 2009, Topics in HIV medicine : a publication of the International AIDS Society, USA.

[8]  C. Armon,et al.  Initiation of HAART at Higher CD4 Cell Counts Is Associated With a Lower Frequency of Antiretroviral Drug Resistance Mutations at Virologic Failure , 2009, Journal of acquired immune deficiency syndromes.

[9]  R. Schooley,et al.  High frequency of clinically significant mutations after first-line generic highly active antiretroviral therapy failure: implications for second-line options in resource-limited settings. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[10]  N. Parkin,et al.  The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy , 2009, AIDS.

[11]  Elena Losina,et al.  HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme , 2009, Antiviral therapy.

[12]  G. Gray,et al.  Costs of Providing Care for HIV-Infected Adults in an Urban HIV Clinic in Soweto, South Africa , 2009, Journal of acquired immune deficiency syndromes.

[13]  S. Hammer,et al.  Persistent minority K103N mutations among women exposed to single-dose nevirapine and virologic response to nonnucleoside reverse-transcriptase inhibitor-based therapy. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  D. Katzenstein,et al.  Envelope Coreceptor Tropism, Drug Resistance, and Viral Evolution Among Subtype C HIV-1-Infected Individuals Receiving Nonsuppressive Antiretroviral Therapy , 2009, Journal of acquired immune deficiency syndromes.

[15]  L. Morris,et al.  HIV type 1 subtype C drug resistance among pediatric and adult South African patients failing antiretroviral therapy. , 2008, AIDS research and human retroviruses.

[16]  H. Schuitemaker,et al.  HIV-1 viral rebound dynamics after a single treatment interruption depends on time of initiation of highly active antiretroviral therapy , 2008, AIDS.

[17]  M. Egger,et al.  Public-Health and Individual Approaches to Antiretroviral Therapy: Township South Africa and Switzerland Compared , 2008, PLoS medicine.

[18]  B. Walker,et al.  Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  S. Lockman.  Prevention of mother-to-child transmission, drug resistance, and implications for response to therapy , 2008, Current opinion in HIV and AIDS.

[20]  A. Puren,et al.  Antiretroviral drug resistance surveillance among drug-naive HIV-1-infected individuals in Gauteng Province, South Africa in 2002 and 2004 , 2008, Antiviral therapy.

[21]  C. Pipper,et al.  [''R"--project for statistical computing]. , 2008, Ugeskrift for laeger.

[22]  J. Crump,et al.  Predictors of incomplete adherence, virologic failure, and antiviral drug resistance among HIV-infected adults receiving antiretroviral therapy in Tanzania. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[23]  R. Paranjape,et al.  High prevalence of human immunodeficiency virus type 1 drug resistance mutations in antiretroviral treatment-experienced patients from Pune, India. , 2007, AIDS research and human retroviruses.

[24]  V. DeGruttola,et al.  The reverse transcriptase 67N 70R 215Y genotype is the predominant TAM pathway associated with virologic failure among HIV type 1C-infected adults treated with ZDV/ddI-containing HAART in southern Africa. , 2007, AIDS research and human retroviruses.

[25]  R. Haubrich,et al.  Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial , 2007, The Lancet.

[26]  D. Kroetz,et al.  Adherence-resistance relationships to combination HIV antiretroviral therapy , 2007, Current HIV/AIDS reports.

[27]  R. Chaisson,et al.  Adherence to Nonnucleoside Reverse Transcriptase InhibitorBased HIV Therapy and Virologic Outcomes , 2007, Annals of Internal Medicine.

[28]  F. Antunes,et al.  Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen , 2007, AIDS.

[29]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[30]  R. Chaisson,et al.  Establishing a workplace antiretroviral therapy programme in South Africa , 2007, AIDS care.

[31]  S. Lawn,et al.  Conservation of First-Line Antiretroviral Treatment Regimen where Therapeutic Options are Limited , 2007, Antiviral therapy.

[32]  Tulio de Oliveira,et al.  An automated genotyping system for analysis of HIV-1 and other microbial sequences , 2005, Bioinform..

[33]  B. G. Gutsche.  Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-Based Antiretroviral Therapy , 2005 .

[34]  D. Katzenstein,et al.  Evolution of resistance to drugs in HIV-1-infected patients failing antiretroviral therapy , 2004, AIDS.

[35]  J. Mary,et al.  Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. , 2004, The New England journal of medicine.

[36]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[37]  Amalio Telenti,et al.  Antiretroviral Treatment of Adult HIV Infection2010 Recommendations of the International AIDS Society–USA Panel , 2010 .

[38]  S. Hammer,et al.  Antiretroviral Treatment of Adult HIV Infection 2008 Recommendations of the International AIDS Society–USA Panel , 2008 .

[39]  S. Miller.  Southern African HIV Clinicians Society guidelines for antiretroviral therapy in adults , 2000 .